Dudediligence.

Alnylam Pharmaceuticals, Inc

ALNYNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$500.9MSep ’24$593.2MDec ’24$594.2MMar ’25$773.7MJun ’25$1.25BSep ’25$1.10BDec ’25$1.17BMar ’26$1.29BJun ’26
Net income, by quarter
−$111.6MSep ’24−$83.8MDec ’24−$18.3MMar ’25−$66.3MJun ’25$251.1MSep ’25$111.5MDec ’25$206.0MMar ’26$164.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$844.3M$1.04B$1.83B$2.25B$3.71B
Gross profit$729.3M$897.2M$1.56B$1.94B$3.04B
Operating income−$708.7M−$785.1M−$282.2M−$176.9M$501.6M
Net income−$852.8M−$1.13B−$440.2M−$278.2M$313.7M
Operating cash flow−$641.7M−$541.3M$104.2M−$8.3M$524.1M
Free cash flow−$718.1M−$613.3M$41.9M−$42.6M$465.4M
Cash$820.0M$866.4M$812.7M$966.4M$1.66B
Shares outstanding120.2M123.9M125.8M129.3M132.4M